ADULT PARENTERAL DRUG MONOGRAPH
GENERIC NAME OF DRUG
propofol
HSC Site
HIGH ALERT MEDICATION
CLASSIFICATION
ALTERNATE NAMES
POSTED PAGE
Sedative 1 of 3
DIPRIVAN, PROPOVEN Apr 2025
ADMINISTRATION POLICY:
1. Moderate (Conscious) Sedation: IV push:
May be administered by a Nurse*, Physician or Respiratory Therapist trained in Moderate
(Conscious) Sedation in any clinical setting staffed/equipped to provide Moderate (Conscious)
Sedation as per Shared Health policy 350.120.106 - HSC - Moderate (Conscious) Sedation
(Adult), St Boniface Hospital policy VI-750 Moderate (Conscious) Sedation (Adult) or WRHA
policy 110.000.010 Moderate Conscious Sedation (Adult). See also LMS Course: Procedural
Sedation and Analgesia.
REQUIRED MONITORING: Sedation and respiratory function as per physician’s order or
applicable policy.
2. Deep Sedation: IV Continuous:
May be administered by a Nurse* in Critical Care, Emergency Department, Post Anesthesia Care
Unit.
High Alert Medication restrictions apply. Refer to Safety Controls for High Alert Medications,
Provincial Clinical Standard
REQUIRED MONITORING: Continuous Cardiac, continuous oxygen saturation and NIBP. To be
administered in intubated and ventilated patients only.
*Refer to site specific terminology/definitions
Adult Parenteral Drug Monographs Terminology/Definitions
Shared Health policy 350.105.103 Critical Elements of Practice Applied to All Patient Care Policies and Procedures
DOSAGE: Note: effects may be enhanced with concomitant sedative or narcotic medications
Usual:
Moderate (Conscious) Sedation:
IV Push: 0.5 to 1 mg/kg followed by 0.25 to 0.5 mg/kg every 1 to 3 minutes as necessary
Deep Sedation:
IV Continuous: Initial: 0.3 mg/kg/hour. Increased by 0.3 to 0.6 mg/kg/hour every 5 to 10 minutes.
Maintenance: 0.3 to 3 mg/kg/hour
Maximum Dose: IV Push: For Moderate (Conscious) Sedation: 200 mg
IV Continuous: 5 mg/kg/hour (higher doses require approval from ICU attending)
RECONSTITUTION/DILUTION/ADMINISTRATION
Supplied as:
10 mg/mL (1%): 20 mL, 50 mL and 100 mL vials
Do not filter. Shake well before use.
IV Push: Administer undiluted over 3 to 5 minutes. Draw up in a syringe JUST PRIOR to use.
ADULT PARENTERAL DRUG MONOGRAPH
GENERIC NAME OF DRUG
propofol
HSC Site
HIGH ALERT MEDICATION
CLASSIFICATION
ALTERNATE NAMES
POSTED PAGE
Sedative 2 of 3
DIPRIVAN, PROPOVEN Apr 2025
IV Continuous: Administer undiluted using vented set. Change bottle and tubing every 12 hours.
Pump Care Pump Line Name Dose Medication Diluent Final Final
Unit/ (Display Name) Mode Volume Volume Concentration
Profile (Container)
(includes
overfill if
applicable)
AGI CC propofol 10mg/mL mg/kg/hr 500 mg/50 mL 50 mL OR 10 mg/mL
OR 100 mL
1,000 mg/100 mL (VIAL)
Commercial vial
INF CC propofol 10 mg/mL mg/kg/hr 500 mg/50 mL 50 mL OR 10 mg/mL
OR mg/kg/hr OR 100 mL
(propofol) 1,000 mg/100 mL (VIAL)
Commercial vial
INF OR propofol 10 mg/mL mcg/kg/min 500 mg/50 mL 50 mL 10 mg/mL
mcg/kg/min Commercial vial (VIAL)
(propofol,)
AGI: Fresenius Kabi Agilia INF: BBraun Infusomat
CC: ADULT Critical Care OR: Operating Room Adult
Maximum Rate: IV Push: over 3 minutes
IV Continuous: 5 mg/kg/h
Maximum Concentration: 20 mg/mL
STABILITY/COMPATIBILITY:
Stability of Solution: 12 hours at room temperature (vial)
6 hours at room temperature (syringe)
Compatibility: Compatible with D5W
Compatible with NaCl 0.9% and Ringers lactate via Y-site
Compatible with heparin, insulin regular and potassium chloride via Y-site
POTENTIAL HAZARDS:
Cardiovascular: bradyarrhythmia, heart failure, hypotension
Dermatologic: rash, pruritus, pain at injection site
Endocrine: hypertriglyceridemia
Gastrointestinal: nausea, vomiting, pancreatitis
Genitourinary: urine discoloration (green)
Immunologic: anaphylaxis
Neurologic: seizure
Musculoskeletal: involuntary muscle movement
Other: Propofol-Related Infusion Syndrome (PRIS): dysrhythmia (eg, bradycardia or tachycardia), heart
failure, hyperkalemia, lipemia, metabolic acidosis, and/or rhabdomyolysis or myoglobinuria with subsequent
renal failure. If PRIS develops, contact physician immediately
Respiratory: apnea, respiratory acidosis
ADULT PARENTERAL DRUG MONOGRAPH
GENERIC NAME OF DRUG
propofol
HSC Site
HIGH ALERT MEDICATION
CLASSIFICATION
ALTERNATE NAMES
POSTED PAGE
Sedative 3 of 3
DIPRIVAN, PROPOVEN Apr 2025
ADDITIONAL NOTES:
1. Use with caution in patients with severe cardiac disease, hypotension, hypertriglyceridemia,
pancreatitis, respiratory disease, epilepsy increased intracranial pressure or impaired cerebral
circulation.
2. Drug is suspended in a fatty emulsion vehicle and contains 10% fat (1.1 kcal/mL). Consider this
source of fat in patients on enteral or parenteral nutrition.
3. Caution in patients with soybean, peanut or egg allergies due to risk of anaphylaxis.
ELDER ALERT: Use a lower induction dose, a slower maintenance rate of administration, and avoid rapidly
delivered boluses to reduce the incidence of unwanted cardiorespiratory depressive events
References available from WRHA Drug Information upon request 204-787-1097, [email protected]
This document was compiled by the Winnipeg Regional Health Authority (WRHA) for use by staff. It is in no way to be considered as medical or other professional advice. The authors, reviewers,
publishers and WRHA shall not be responsible for errors, inaccuracies or continued completeness contained herein. The information in this document should not be used or relied upon to replace the skill
and professional judgment required when determining appropriate patient care or treatment, or as a substitute for specific medical advice from a licensed health care practitioner. The authors, reviewers,
publishers and WRHA disclaim all legal liability in respect to the contents herein. The information herein should be used as a guideline for reference purposes only. Copyright in this document is held by
the Winnipeg Regional Health Authority. This document may not be copied, reproduced, altered, published or used to create derivative works. It may be used and displayed for educational purposes or as
a guideline for reference purposes only and may be not broadcast or further distributed without the written consent of the WRHA.
